The government’s regulatory agencies last week lashed out at a Hong Kong consortium’s plan to sell 30 percent of its stake in Nan Shan Life Insurance Co to Chinatrust Financial Holding Co. However, the Nan Shan deal has also put the regulatory agencies’ credibility to the test, with the public watching closely if they will approve the deal eventually.
On Tuesday, Hong Kong-listed China Strategic Holdings Ltd — which, along with private equity fund Primus Financial Holdings Ltd, had purchased a 97.57 percent stake in Nan Shan last month from American International Group Inc (AIG) for approximately US$2.15 billion — announced unexpectedly that it planned to sell 30 percent of the Nan Shan shares to Chinatrust Financial for US$660 million.
In exchange, Chinatrust Financial would sell 9.95 percent of its shares to China Strategic for NT$20.79 billion (US$643 million) via a private placement. Chinatrust Financial said it also reserved the right to increase its shareholding in Nan Shan within three years.
This new deal between China Strategic and Chinatrust Financial has pretty much blown a hole in the commitment the Hong Kong consortium made earlier to the Financial Supervisory Commission, in which it said that, once it wins regulatory approval for its deal with AIG, it would maintain a long-term stake and run the company for a minimum of seven years.
But what has actually raised people’s eyebrows is the identity of the people — or the power — behind the Hong Kong consortium — especially China Strategic.
On Nov. 10, China Strategic, a battery manufacturing and securities investment company, appointed former Hong Kong commerce secretary Frederick Ma (馬時亨) as chairman and former Hang Seng Bank chief executive Raymond Or (柯清輝) as its chief executive officer. Its shareholding structure is also a mystery, raising concern in Taiwan that it might include Chinese nationals. Taiwanese regulations still prohibit Chinese investment in the local financial sector.
Given these concerns, the Investment Commission last Friday demanded that the company submit more documentation about its shareholding structure and the nationalities of shareholders before entering into a formal review of the Nan Shan deal.
The deal has raised a number of questions. Why is China Strategic planning to sell part of its Nan Shan holding to Chinatrust Financial even before it has received regulatory approval to buy AIG’s stake in Nan Shan? Is it simply a tactic to gain regulatory approval by partnering with a major financial conglomerate in Taiwan?
As for AIG, how does it view this deal with the consortium? Has China Strategic broken AIG’s bidding rules by agreeing to sell a stake in Nan Shan to Chinatrust Financial?
When the Hong Kong consortium outbid Chinatrust Financial last month to acquire AIG’s Nan Shan shares, AIG said the winning bidder was chosen because it presented the greatest long-term stability and potential to Nan Shan. Will AIG now agree to the consortium teaming up with Chinatrust Financial after initially rejecting Chinatrust?
This conundrum has raised suspicions whether the government is under pressure to approve the Hong Kong consortium’s deal with AIG, which is nearly 80 percent owned by the US government. The ownership transfer of Nan Shan has great implications for its 4 million policyholders, approximately 4,000 employees and more than 34,000 agents in Taiwan. There is too much at stake for the regulatory agencies to take this issue lightly.
US aerospace company Boeing Co has in recent years been involved in numerous safety incidents, including crashes of its 737 Max airliners, which have caused widespread concern about the company’s safety record. It has recently come to light that titanium jet engine parts used by Boeing and its European competitor Airbus SE were sold with falsified documentation. The source of the titanium used in these parts has been traced back to an unknown Chinese company. It is clear that China is trying to sneak questionable titanium materials into the supply chain and use any ensuing problems as an opportunity to
It’s not every month that the US Department of State sends two deputy assistant secretary-level officials to Taiwan, together. Its rarer still that such senior State Department policy officers, once on the ground in Taipei, make a point of huddling with fellow diplomats from “like-minded” NATO, ANZUS and Japanese governments to coordinate their multilateral Taiwan policies. The State Department issued a press release on June 22 admitting that the two American “representatives” had “hosted consultations in Taipei” with their counterparts from the “Taiwan Ministry of Foreign Affairs.” The consultations were blandly dubbed the “US-Taiwan Working Group on International Organizations.” The State
The Chinese Supreme People’s Court and other government agencies released new legal guidelines criminalizing “Taiwan independence diehard separatists.” While mostly symbolic — the People’s Republic of China (PRC) has never had jurisdiction over Taiwan — Tamkang University Graduate Institute of China Studies associate professor Chang Wu-ueh (張五岳), an expert on cross-strait relations, said: “They aim to explain domestically how they are countering ‘Taiwan independence,’ they aim to declare internationally their claimed jurisdiction over Taiwan and they aim to deter Taiwanese.” Analysts do not know for sure why Beijing is propagating these guidelines now. Under Chinese President Xi Jinping (習近平), deciphering the
Many local news media last week reported that COVID-19 is back, citing doctors’ observations and the Centers for Disease Control’s (CDC) statistics. The CDC said that cases would peak this month and urged people to take preventive measures. Although COVID-19 has never been eliminated, it has become more manageable, and restrictions were dropped, enabling people to return to their normal way of life due to decreasing hospitalizations and deaths. In Taiwan, mandatory reporting of confirmed cases and home isolation ended in March last year, while the mask mandate at hospitals and healthcare facilities stopped in May. However, the CDC last week said the number